Analysis of molecular mechanism forEML4-ALK/ EGFR-TKI resistance and establishment of less invasive diagnosis.
Project/Area Number |
25462202
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory surgery
|
Research Institution | University of Occupational and Environmental Health, Japan |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
SO Tomoko 産業医科大学, 医学部, 講師 (00341529)
TANAKA Fumihiro 産業医科大学, 医学部, 教授 (10283673)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | EML4-ALK / EGFR-TKI / 耐性 / 診断 / 循環腫瘍細胞 |
Outline of Final Research Achievements |
Lung cancer is the leading cause of cancer deaths, which is mainly caused by its resistance to conventional treatment modalities. In fact, some targeting agents are very active to specific population of patients, but most patients who had once responded to these agents finally experience disease progression. The aim of the current study is to reveal biological mechanism of drug resistance using clinical materials, and to develop and establish clinically useful modalities to detect drug resistance. In the study, we identified MED12 as an important molecule associated with resistance to some targeting agents, and documented positive expression of MED12 in 92% of 89 lung cancer tissues. In addition, we have developed a novel detection system of circulating tumor cell (CTC). The CTC-chip system, an alternative of the CellSearch system, has provided sensitive efficiency of 85% in capturing tumor cells spiked in the blood, and can be potentially useful for clinical use.
|
Report
(3 results)
Research Products
(31 results)
-
[Journal Article] ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.2016
Author(s)
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Munoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.
-
Journal Title
PLoS One
Volume: 11(1)
Issue: 1
Pages: e0147344-e0147344
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
[Journal Article] rognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)2015
Author(s)
Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M
-
Journal Title
Lung Cancer
Volume: 90
Issue: 3
Pages: 548-53
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
[Journal Article] Erlotinib resistance in lung cancer cells mediated by integrinβ1/Src/Akt-driven bypass signaling2013
Author(s)
Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, Kuwano M, Ono M(12人中9番目)
-
Journal Title
Cancer Res
Volume: 73
Pages: 6243-53
Related Report
Peer Reviewed
-
-
[Journal Article] Clinical Significance of Expression of Cancer/testis Antigen and Down-regulation of HLA Class-I in Patients with Stage I Non-small Cell Lung Cancer2013
Author(s)
Hanagiri T, Shigematsu Y, Shinohara S, Takenaka M, Oka S, Chikaishi Y, Nagata Y, Baba T, Uramoto H, So T, Yamada S(11人中9番目)
-
Journal Title
Anticancer Res
Volume: 33
Pages: 2123-8
Related Report
Peer Reviewed
-
-
-
[Journal Article] Intrapleural chemotherapy improves the survival of non-small cell lung cancer patients with positive pleural lavage cytology.2013
Author(s)
Baba T, Uramoto H, Kuwata T, Takenoyama M, Chikaishi Y, Oka S, Nagata Y, Shigematsu Y, Shimokawa H, Nakagawa M, So T, Hanagiri T, Tanaka F.
-
Journal Title
Surg Today
Volume: 43
Issue: 6
Pages: 648-53
DOI
NAID
Related Report
Peer Reviewed
-
[Journal Article] Serum Level of Osteopontin as a Prognostic Factor in Patients Who Underwent Surgical Resection for Non-Small-Cell Lung Cancer2013
Author(s)
Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Yamada S, Tanaka F(13人中10番目)
-
Journal Title
Clin Lung Cancer
Volume: 14
Issue: 3
Pages: 288-94
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer2013
Author(s)
Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, Uramoto H, So T, Takenoyama M, Tanaka F(12人中9番目)
-
Journal Title
J Surg Res
Volume: 181
Pages: 57-63
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
[Presentation] Novel malignant-mesothelioma-associated antigens (Gene-X and THBS-2) in the diagnosis of malignant pleural mesothelioma (MPM)2013
Author(s)
Tanaka F, Shigematsu Y, Hanagiri T, Uramoto H, So T, Yoneda K, Takuwa T, Hashimoto M, Matsumoto S, Okumura Y, Kondo N, Hasegawa S
Organizer
49th American Society of clinical oncology
Place of Presentation
Chicago,USA
Related Report
-
[Presentation] Development of detecting systems for circulating tumor cells in malignant pleural mesothelioma patients2013
Author(s)
Chikaishi Y, So T, Oka S, Takenaka M, Nakagawa M, Shimokawa H, Iwata T, Nagata Y, Uramoto H, Hanagiri T, Ohnaga T, Uramoto H, Tanaka F
Organizer
AACR (The American Association for Cancer Research) Meeting
Place of Presentation
Washington,USA
Related Report